Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Yкраїнський (UK)
Przejdź do strony domowej biblioteki Centralna Biblioteka Wojskowa Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaCentralna Biblioteka Wojskowa

Wyszukujesz frazę "renal cell carcinoma" wg kryterium: Temat

  Lista filtrów
Wyrównaj
Wyświetlanie 1-15 z 23
Tytuł:
Hypothyroidism caused by cabozantinib therapy of clear cell renal cell carcinoma – case report, own experience
Autorzy:
Buraczewska, Agnieszka
Kardas, Joanna
Młot, Beata
Solarek, Wojciech
Waśko-Grabowska, Anna
Powiązania:
https://bibliotekanauki.pl/articles/1062936.pdf
Data publikacji:
2017
Wydawca:
Medical Education
Tematy:
cabozantinib
hypothyroidism
renal cell carcinoma
Opis:
Cabozantinib, the latest available in Poland medication for the treatment of renal cell carcinoma, registered in this indication by the European Medicines Agency (EMA) in September 2016, has been available in several cancer centers in Poland since November 2016 as part of the expanded access program. Primary hypothyroidism is a common complication during thyrosine kinase inhibitors (TKI) treatment, although there are few reports of its occurrence during treatment with cabozantinib, which belongs to this medication group. We present a case of rapid development of clinically apparent hypothyroidism after cabozantinib treatment and report data on this complication in the group of our patients.
Źródło:
OncoReview; 2017, 7, 3; 121-125
2450-6125
Pojawia się w:
OncoReview
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Retrospective assessment of everolimus treatment in patients suffering from advanced renal cell carcinoma
Autorzy:
Hernik, Paweł
Kruczała, Maksymilian
Ziobro, Marek
Powiązania:
https://bibliotekanauki.pl/articles/773514.pdf
Data publikacji:
2017
Wydawca:
Medical Education
Tematy:
everolimus
renal cell carcinoma
targeted therapy
Opis:
Objective: Results of second-line everolimus treatment in clear cell renal carcinoma. Material and methods: Clinical data of 32 patients of the Clinic of Systemic and Metastatic Malignancies, Centre of Oncology, Maria Sklodowska-Curie Memorial Institute (Krakow Branch) treated with second-line everolimus between 2011 and 2016 were analysed. Results: Median progression-free survival was 7 months. Stable disease was observed in 24 cases. Adverse events occurred in 59% of all patients, and the majority were mild and moderate (G1 and G2) according to CTCAE. The most frequent adverse events included anaemia, stomatitis, rash and fatigue. Conclusion: Molecularly targeted drugs offer the only effective and available therapy in Poland, which can be administered in patients with advanced renal cell carcinoma. Second-line everolimus is a valuable therapeutic option in the above mentioned group (following progression on first-line TKI therapy), especially when it is necessary to avoid the accumulation of similar adverse events after TKI treatment (different toxicity profiles).
Źródło:
OncoReview; 2017, 7, 2; 88-91
2450-6125
Pojawia się w:
OncoReview
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Papillary renal cell carcinoma – case report of a patient with disseminated disease treated with pazopanib with several years of survival against reviewing current literature
Autorzy:
Buraczewska, Agnieszka
Kardas, Joanna
Powiązania:
https://bibliotekanauki.pl/articles/1064903.pdf
Data publikacji:
2016
Wydawca:
Medical Education
Tematy:
molecular targeted therapies
papillary renal cell carcinoma
Opis:
Papillary renal cell carcinoma is the second most common histological type of renal cell carcinoma with distinct cytogenetics, histology and prognosis. It exhibits significantly poorer response to molecular targeted therapies, which are about the progress in clear cell carcinoma. We present an overview of the treatment trials and report a casuistic case of metastatic disease controlled for several years with pazopanib.
Źródło:
OncoReview; 2016, 6, 2; A62-65
2450-6125
Pojawia się w:
OncoReview
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Patient with metastatic renal cell carcinoma treated successfully with pazopanib for four years.
Autorzy:
Słowik, Agnieszka
Streb, Joanna
Chrzan, Robert
Krzemieniecki, Krzysztof
Powiązania:
https://bibliotekanauki.pl/articles/1065279.pdf
Data publikacji:
2015
Wydawca:
Medical Education
Tematy:
metastatic renal cell carcinoma
pazopanib
tyrosine kinase inhibitors
Opis:
We present a case of a patient with metastatic renal cell carcinoma who was treated with pazopanib in the first-line treatment. Although nephrectomy was not performed, there was a positive reaction to the therapy with multi-targeted tyrosine kinase inhibitor. After 18 months of the palliative treatment, the cancerous kidney was surgically removed and pazopanib was restarted with the effect of further disease remission. The development of hypertension, complete hair discoloration and isolated hyperbilirubinemia occurred, and there was occasionally hypokalaemia in laboratory findings within 48 months of therapy. No serious adverse events were reported.
Źródło:
OncoReview; 2015, 5, 3; A109-116
2450-6125
Pojawia się w:
OncoReview
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Everolimus-induced interstitial lung disease in patient with metastatic renal cell carcinoma – case report and literature review
Autorzy:
Buraczewska, Agnieszka
Kardas, Joanna
Powiązania:
https://bibliotekanauki.pl/articles/1065282.pdf
Data publikacji:
2015
Wydawca:
Medical Education
Tematy:
everolimus
interstitial lung disease
metastatic renal cell carcinoma
Opis:
We present a case of a 70-year-old man with metastatic renal cell carcinoma treated with second-line everolimus after rapid progression on first-line tyrosine kinase inhibitor, in whom a side effect of the therapy occurred in the form of a drug-induced interstitial lung disease. We also provide a review of the literature concerning opinions on incidence, clinical picture, consequences and management of the complication discussed.
Źródło:
OncoReview; 2015, 5, 3; A117-121
2450-6125
Pojawia się w:
OncoReview
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Metastasis of clear cell renal cell carcinoma to the organs of the head and neck – an ongoing problem
Autorzy:
Torchalla, Patrycja
Czesak, Małgorzata
Osuch-Wójcikiewicz, Ewa
Powiązania:
https://bibliotekanauki.pl/articles/1398949.pdf
Data publikacji:
2021
Wydawca:
Index Copernicus International
Tematy:
clear cell renal cancer
renal cell carcinoma
metastases
submandibular salivary gland
Opis:
Renal cell carcinoma accounts for about 2-3% of all malignancies. It is characterized by a high frequency of metastases, which are most often observed in the lungs, bones, liver, brain and regional lymph nodes. Literature highlights the rare occurrence of renal cancer metastases to the head and neck, even though it is the third most common cancer that metastasizes to the head and neck. Below we present a case report of metastases of clear cell carcinoma from a kidney to the organs of the head and neck. The analysis was carried out retrospectively based on medical records of a patient hospitalized at the Department of Otorhinolaryngology, Head and Neck Surgery of the Medical University of Warsaw in the years 2009-2019. We describe an 81-year-old man after left-sided nephrectomy due to clear cell carcinoma, with numerous distant metastases, who was diagnosed with metastases to the left submandibular salivary gland 8 years after primary surgery, followed by a diagnosis of metastasis to the right submandibular salivary gland 3 years later. The patient underwent 2 radical procedures to remove the submandibular salivary glands. Due to the presence of lung metastases, treatment with a tyrosine kinase inhibitor was also implemented.
Źródło:
Polski Przegląd Otorynolaryngologiczny; 2021, 10, 1; 42-48
2084-5308
2300-7338
Pojawia się w:
Polski Przegląd Otorynolaryngologiczny
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Reduced expression of E-cadherin and increased sialylation level in clear cell renal cell carcinoma
Autorzy:
Borzym-Kluczyk, Małgorzata
Radziejewska, Iwona
Cechowska-Pasko, Marzanna
Darewicz, Barbara
Powiązania:
https://bibliotekanauki.pl/articles/1038588.pdf
Data publikacji:
2017
Wydawca:
Polskie Towarzystwo Biochemiczne
Tematy:
clear cell renal cell carcinoma
E-cadherin
lectins
sialyl Lewis antigens
Opis:
Cancer cells are characterized by an aberrant increase in protein N-glycosylation and by disruption of E-cadherin-mediated adherens junctions. However, the relationship between alterations in N-glycosylation process and loss of E-cadherin adhesion in cancer remains unclear. The mechanisms of altered expression of adhesive glycoproteins in cancer cells have not been fully elucidated. Thus, the aim of this study was to examine the expression of E-cadherin and sialyl Lewisa/x, NeuAcα2-3Gal, NeuAcα2-6Gal/GalNAc structures in the normal renal tissue and intermediate and cancerous tissues from patients with clear cell RCC. Moreover, we attempted to correlate the E-cadherin expression with some specific sugar residues of renal cancer tissue glycoproteins. The expression of E-cadherin was analysed using ELISA test and immunoblotting. Oligosaccharide structures and sialylation level were detected with ELISA test using specific biotinylated lectins or antibodies. A significant decrease of E-cadherin expression as well as a significant increase in sialylated oligosaccharides level in intermediate zone and renal cancer tissue in comparison to normal renal tissue are reported. Significant decrease in expression of cadherins and increase in sialylation of oligosaccharide structures in renal cancer tissue in comparison to normal renal tissue, and in renal cancer tissue in comparison to intermediate zone of renal tissue, are important for the future research concerning detection and quantification of cadherins and sialylated oligosaccharide structures in urine and cells of urinary sediment as possible non-invasive marker of early RCC.
Źródło:
Acta Biochimica Polonica; 2017, 64, 3; 465-470
0001-527X
Pojawia się w:
Acta Biochimica Polonica
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Diffusion weighted imaging in differentiation of the clear cell RCC from the major non-clear cell RCC subtypes
Autorzy:
Kış, Naciye
Erok, Berrin
Powiązania:
https://bibliotekanauki.pl/articles/2040173.pdf
Data publikacji:
2021-09-30
Wydawca:
Uniwersytet Rzeszowski. Wydawnictwo Uniwersytetu Rzeszowskiego
Tematy:
apparent diffusion coefficient
diffusion weighted imaging
renal cell carcinoma
Opis:
Introduction. Renal cell carcinoma (RCC) is the most common malignant renal tumor in adults accounting for 80-90% of primary malignant adult renal neoplasms. RCC represents a very heterogenous groups of tumors with a number of distinct histological varieties, of which the major 3 subtypes are clear cell RCC (70-80%), papillary RCC (13-20%), and chromophobe RCC (5%). Imaging features are varied from solid and relatively homogenous appearance to markedly heterogenous appearance with cystic changes, hemorrhage and necrosis. The use of diffusion weighted imaging (DWI) for RCC subtyping and also for differentiation of high grade and low grade tumors has been showed to be useful in many studies in the literature. Aim. In this study, we aimed to determine the comparative contribution of DWI in differentiation of the clear cell RCC from the major non-clear cell RCC subtypes at standard high b-value (1000 s/mm2) versus low b-value (500 s/mm2). In addition, we also aimed to assess the diagnostic performance of DWI for differentiating high grade clear cell RCC from low grade clear cell RCC based on Fuhrman grades in our patients. Material and methods. 62 cases with a prediagnosis of RCC according to MRI findings including DWI sequence with histological verification and subtyping of renal cortical tumor following a total or partial nephrectomy were included in the study. Results. Among 62 cases, 46 were male and 16 were female, with mean age of 59.5±15.7. Pathological diagnoses of 62 cases were as follows, clear cell RCC, (44) papillary cell RCC (14) and chromophobe cell RCC (4). They were divided into two groups as clear cell RCC group (44 cases) and non-clear cell RCC group (18 cases). There was no statistically significant difference between the mean ADC values of clear cell and non-clear cell groups at b-value of 1000 s/mm2 (p>0.05). However, the mean ADC level for clear cell RCC group at b-value of 500 s/mm2 were significantly higher than for non-clear cell RCC group (p<0.05). When a value of 0.99x10-3 mm2/s was set as cut-off for ADC at b-factor of 500 s/mm2, differentiation was achieved with a high sensitivity (91%) and specificity (56%). Regarding the diagnostic performance of DWI for differentiating high from low Fuhrman grades clear cell RCCs, there was no statistically significant difference between the ADC values of Grade I-II clear cell RCC cases and Grade III-IV clear cell RCC cases at b-factor of 1000 s/mm2 (p>0.05). However, ADC values for grade III-IV group was statistically significantly lower than ADC values for Grade I-II group at b-factor of 500 s/mm2 level. Conclusion. ADC measurements at moderate b-value of 500 s/mm2 were more sensitive in subtyping and grading of RCC cases. This technique can be used in clinical practice as a fast and additional sequence in abdominal MRI.
Źródło:
European Journal of Clinical and Experimental Medicine; 2021, 3; 215-220
2544-2406
2544-1361
Pojawia się w:
European Journal of Clinical and Experimental Medicine
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Sarcomatoid renal-cell carcinoma: treatment strategy, review of the literature and a case report
Autorzy:
Gębara-Puchniarz, Agnieszka
Hryciuk, Beata
Stec, Rafał
Szczylik, Cezary
Grala, Bartłomiej
Kozłowski, Wojciech
Powiązania:
https://bibliotekanauki.pl/articles/1064804.pdf
Data publikacji:
2016
Wydawca:
Medical Education
Tematy:
chemotherapy
doxorubicin
gemcitabine
sarcomatoid renal-cell carcinoma
surgical treatment
Opis:
Introduction: Sarcomatoid renal-cell carcinoma is a very rare cancer characterised with aggressive course of disease and poor prognosis. At present there are no standards of care for this histologic subtype of renal cell carcinoma resistant to various forms of systemic treatment. Methods: The study describes a case of 58 year old woman after left nephrectomy for clear cell carcinoma with sarcomatoid component and after resection of right-kidney tumour for synchronous clear cell carcinoma who received first-line bevacizumab and temsirolimus under the clinical trial, and then second-line chemotherapy based on gemcitabine and doxorubicin and ifosfamide-based third-line chemotherapy. The patient underwent pulmonary metastasectomy twice, and once a metastasectomy for liver metastases. Conclusions: Surgery (including metastases treatment) followed by the systemic chemotherapy seems to be correct option of treatment in patients with renal cell carcinoma with sarcomatoid features. The development of optimum method of systemic treatment requires further prospective randomised trials.
Źródło:
OncoReview; 2016, 6, 4; A184-187
2450-6125
Pojawia się w:
OncoReview
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Bilateral renal cell carcinoma with bilateral synchronous adrenal gland metastases – a case report
Autorzy:
Hadzi-Djokic, J.
Andrejevic, Vladan
Pejcic, T.
Djurasic, L.
Acimovic, M.
Dzamic, Z.
Powiązania:
https://bibliotekanauki.pl/articles/1395713.pdf
Data publikacji:
2014-02-01
Wydawca:
Index Copernicus International
Tematy:
bilateral renal cell carcinoma
bilateral adrenal gland metastases
radical nephrectomy
partial nephrectomy
Opis:
The authors reported a case of a 52-year-old patient with bilateral synchronous renal cell carcinoma synchronously disseminated in adrenal glands is presented. The patient underwent surgical treatment: radical nephrectomy on the right side, bilateral adrenectomie on the right and partial nephrectomy on the left side. Five years after surgery, patient is in complete remission
Źródło:
Polish Journal of Surgery; 2014, 86, 2; 97-99
0032-373X
2299-2847
Pojawia się w:
Polish Journal of Surgery
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
αB-crystallin as a promising target in pathological conditions - a review
Autorzy:
Maksymiuk, M.
Sabiborowicz, A.
Tuzimek, A.
Deptała, A.
Czerw, A.
Badowska-Kozakiewicz, A.M.
Powiązania:
https://bibliotekanauki.pl/articles/2086060.pdf
Data publikacji:
2020
Wydawca:
Instytut Medycyny Wsi
Tematy:
αB-crystallin
small heat-shock proteins
breast cancer
renal cell carcinoma
Opis:
Introduction and objective. αB-crystallin belongs to the ubiquitous family of small heat-shock proteins. It was discovered as a physiological protein of the eye lens, maintaining its liquid-like property. Furthermore, αB-crystallin was proved to playa bipolar role in both physiological and pathophysiological conditions. This review discusses current knowledge about the biology and genetics of αB-crystallin, and summarizes recent advances in understanding its role in ophthalmic and neurological disorders, as well as breast cancer, renal cancer and other malignancies. State of knowledge. α-crystallins are established as important elements of the protein quality control network, and consequently their defects are related to multiple human diseases. New studies highlight αB-crystallin’s involvement in proliferative diabetic retinopathy angiogenesis and point out its therapeutic potential in age-related macular degeneration. αB-crystallin is thought to be associated with the disease-causing protein aggregates, leading to its connection with such neurological disturbances as anaplastic astrocytoma, Parkinson disease, aging deficits in the peripheral nervous system and multiple sclerosis. In breast cancer, it was proven to be a marker of aggressive behaviur and cerebral metastases. Strong expression of αB-crystallin promoted growth and migration of clear cell renal cell carcinoma cells and was correlated with lower overall survival rate. Considering other malignancies, its various roles were established in colorectal and gastric cancers, head and neck squamous cell carcinomas and osteosarcomas. Conclusions. Further studies concerning αB-crystallin seem to be enormously promising, as they might improve our understanding of common human pathologies as well as contemporary diagnostics and treatment.
Źródło:
Annals of Agricultural and Environmental Medicine; 2020, 27, 3; 326-334
1232-1966
Pojawia się w:
Annals of Agricultural and Environmental Medicine
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
The first line therapy for intermediate/ high risk patients with advanced renal cell carcinoma according to therapeutic program B.10
Autorzy:
Żołnierek, Jakub
Powiązania:
https://bibliotekanauki.pl/articles/22792533.pdf
Data publikacji:
2023-08-19
Wydawca:
Medical Education
Tematy:
renal cell carcinoma
intermediate risk group
unfavourable risk group
tyrosine kinases inhibitor
immune check-point inhibitor
Opis:
The purpose of this article is to discuss the use of therapeutic options for the first-line systemic treatment of patients with advanced renal cell carcinoma under the B.10 drug program effective in Poland as of May 2022 - with a focus on intermediate and high-risk patient populations according to the IMDC. The specific situation created by reimbursement conditions with the exclusion of regimens combined with a tyrosine kinase inhibitor and immune checkpoint inhibitors along with the marginalisation of the use of an mTOr inhibitor necessitates a choice between two-drug immunotherapy or an antian giogenic drug in monotherapy. In this context, choosing the right treatment in the context of specific clinical situations is a challenge.
Źródło:
OncoReview; 2023, 13, 2; 48-57
2450-6125
Pojawia się w:
OncoReview
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Matrix metalloproteinases in urinary system tumours. Part I - Matrix metalloproteinases in renal cell carcinoma
Autorzy:
Młynarczyk, G.
Kudelski, J.
Darewicz, B.
Galewska, Z.
Romanowicz, L.
Powiązania:
https://bibliotekanauki.pl/articles/1918434.pdf
Data publikacji:
2017
Wydawca:
Uniwersytet Medyczny w Białymstoku
Tematy:
Extracellular matrix
matrix metalloproteinases
urinary tract tumours
renal clear cell carcinoma
Opis:
Extracellular matrix metalloproteinases - MMPs, also referred to as matrixines, provide a group of proteolytic enzymes. They belong to the family of endopeptidases that break down elements of extracellular matrix, resulting in its continuous remodelling. Their activity is regulated at multiple levels, while tissue inhibitors of metalloproteinases play a major role in this process. Metalloproteinases play a significant part in neoplastic processes due to their contribution to local tumour invasion and formation of distant metastases, as well as to angiogenesis Urinary tract tumours pose a significant diagnostic and therapeutic challenge and their incidence tends to grow every year. The aim of this part of review is to describe extracellular matrix and matrix metalloproteinases and to highlight the contribution of matrix metalloproteinases in the development of renal clear cell carcinoma.
Źródło:
Progress in Health Sciences; 2017, 7(1); 161-168
2083-1617
Pojawia się w:
Progress in Health Sciences
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Contralateral adrenal metastasis from renal cell carcinoma with tumor thrombus in the adrenal vein: a case report
Przerzut raka nerkowokomórkowego do przeciwległego nadnercza z czopem nowotworowym w żyle nadnerczowej: opis przypadku
Autorzy:
Piotrowicz, Sebastian
Muśko, Natalia
Kozikowski, Mieszko
Nyk, Łukasz
Borówka, Andrzej
Dobruch, Jakub
Powiązania:
https://bibliotekanauki.pl/articles/1053019.pdf
Data publikacji:
2015
Wydawca:
Medical Communications
Tematy:
adrenal metastasis
adrenal vein
contralateral
renal cell carcinoma
tumor thrombus
czop nowotworowy
przeciwległy
przerzut do nadnercza
rak nerkowokomórkowy
żyła nadnerczowa
Opis:
A 64-year-old woman presented with contralateral right adrenal metastasis with adrenal vein thrombus, which was diagnosed many years after left nephrectomy with adrenalectomy due to renal cell cancer. The patient underwent right adrenalectomy with adrenal vein tumor thrombectomy for treatment. The pathologic examination confirmed metastatic clear cell carcinoma. The remote but existing risk of developing contralateral adrenal metastasis (CAM) after primary radical nephrectomy supports the idea of sparing the adrenal gland in suitable patients who undergo radical nephrectomy. Contralateral adrenal metastasis from RCC is a rare finding with the potential benefit of cure after resection. Care must be taken in preoperative diagnostics, as this metastasis is capable of causing inferior vena cava tumor thrombus via the suprarenal venous route. According to our knowledge, our case is the second similar entity described in literature so far.
U 64-letniej chorej stwierdzono przerzut do przeciwległego nadnercza wraz z obecnością czopu nowotworowego w żyle nadnerczowej, który został rozpoznany wiele lat po lewostronnej nefrektomii wraz z adrenalektomią, wykonanej z powodu raka nerkowokomórkowego. Pacjentka została poddana prawostronnej adrenalektomii z usunięciem czopa nowotworowego z żyły nadnerczowej. W badaniu histopatologicznym potwierdzono przerzut raka jasnokomórkowego. Ryzyko wystąpienia przerzutu do przeciwległego nadnercza po pierwotnej radykalnej nefrektomii istnieje, choć jest niewielkie, dlatego zasadne wydaje się zachowanie nadnercza w wybranej grupie chorych poddawanych radykalnej nefrektomii. Występowanie zmian wtórnych raka nerkowokomórkowego w przeciwległym nadnerczu jest rzadko spotykane, natomiast resekcja guza wiąże się z możliwością wyleczenia. Konieczna jest staranna diagnostyka przedoperacyjna w związku ze zdolnością przerzutu raka nerkowokomórkowego do tworzenia czopa nowotworowego w żyle głównej dolnej drogą żył nadnerczowych. Wedle wiedzy autorów niniejszy przypadek jest drugim tego rodzaju opisywanym dotąd w literaturze przedmiotu.
Źródło:
Journal of Ultrasonography; 2015, 15, 63; 438-442
2451-070X
Pojawia się w:
Journal of Ultrasonography
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Metabolomic analysis of biological material using LC-MS in the quest for urinary system cancer biomarkers - review
Autorzy:
Szuberla, Wiktoria
Wrona, Maria
Powiązania:
https://bibliotekanauki.pl/articles/31342652.pdf
Data publikacji:
2024
Wydawca:
Politechnika Rzeszowska im. Ignacego Łukasiewicza. Oficyna Wydawnicza
Tematy:
mass spectrometry
metabolomics
LC-MS
kidney cancer
renal cell carcinoma
bladder cancer
spektrometria mas
metabolomika
rak nerki
rak nerkowokomórkowy
rak pęcherza moczowego
Opis:
Renal cell carcinoma (RCC) and bladder cancer (BC) are among the most frequently diagnosed urinary system cancers worldwide. They are characterized by high mortality and recurrence rates. In response to the rising incidence and mortality rates, scientists are exploring innovative diagnostic and therapeutic methods. Metabolomics, which analyzes metabolite levels, may enable early diagnosis and monitoring of therapy progress. Compared to other omics technologies, it focuses on the outcomes of metabolite activity, providing a unique perspective on processes occurring in cancer cells. Metabolomic analyses utilize techniques such as mass spectrometry. These methods allow the identification of biomarkers and precise determination of the chemical composition of biological samples. However, the most commonly used method is liquid chromatography-mass spectrometry (LC-MS), which enables the most comprehensive screening of cancer metabolomes. Recent studies show significant progress in recognizing characteristic metabolites associated with urological cancers, although this area remains partially unexplored. Research on circulating metabolites, especially those present in easily accessible samples like blood or urine, demonstrates promising potential in clinical practice. Study results reveal differences in metabolic profiles between various stages of cancer development, which may have clinical significance. The future of this field involves an increasing number of clinical cohorts, standardization of sample preparation, and further improvements in instrument sensitivity and speed. LC-MS-based metabolomics has the potential to contribute to the improvement of diagnostics, therapy, and the quality of life of patients with some urological cancers. However, challenges, such as the lack of uniform methodologies and understanding of metabolite determinants, require further research and innovation.
Źródło:
Chemical Technology & Biotechnology; 2024, 4; 70-75
2720-6793
Pojawia się w:
Chemical Technology & Biotechnology
Dostawca treści:
Biblioteka Nauki
Artykuł
Wyświetlanie 1-15 z 23

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies